Role of Posttranslational Modifications of Proteins in Cardiovascular Disease

Overview

Journal Oxid Med Cell Longev

Publisher Wiley

Specialties Cell Biology
Endocrinology

Date 2022 Jul 20

PMID 35855865

Authors

Yong-Ping Liu

Tie-Ning Zhang

Ri Wen

Chun-Feng Liu

Ni Yang

Affiliations

Soon will be listed here.

Abstract

Cardiovascular disease (CVD) has become a leading cause of mortality and morbidity globally, making it an urgent concern. Although some studies have been performed on CVD, its molecular mechanism remains largely unknown for all types of CVD. However, recent in vivo and in vitro studies have successfully identified the important roles of posttranslational modifications (PTMs) in various diseases, including CVD. Protein modification, also known as PTMs, refers to the chemical modification of specific amino acid residues after protein biosynthesis, which is a key process that can influence the activity or expression level of proteins. Studies on PTMs have contributed directly to improving the therapeutic strategies for CVD. In this review, we examined recent progress on PTMs and highlighted their importance in both physiological and pathological conditions of the cardiovascular system. Overall, the findings of this review contribute to the understanding of PTMs and their potential roles in the treatment of CVD.

Citing Articles

Sex-specific mechanisms of cerebral microvascular BK dysfunction in a mouse model of Alzheimer's disease.

Silva J, Polk F, Martin P, Thai S, Savu A, Gonzales M Alzheimers Dement. 2024; 21(2):e14438.

PMID: 39698895 PMC: 11848394. DOI: 10.1002/alz.14438.

New insights into the pharmacological inhibition of SRF activity: Key inhibitory targets and mechanisms.

Wong D, Qiu H Vascul Pharmacol. 2024; 157():107443.

PMID: 39586415 PMC: 11648470. DOI: 10.1016/j.vph.2024.107443.

Recent advances in serum response factor posttranslational modifications and their therapeutic potential in cardiovascular and neurological diseases.

Visconti A, Qiu H Vascul Pharmacol. 2024; 156:107421.

PMID: 39209126 PMC: 11626983. DOI: 10.1016/j.vph.2024.107421.

Atherosclerosis antigens as targets for immunotherapy.

Raposo-Gutierrez I, Rodriguez-Ronchel A, Ramiro A Nat Cardiovasc Res. 2024; 2(12):1129-1147.

PMID: 39196152 DOI: 10.1038/s44161-023-00376-x.

Tailored Viral-like Particles as Drivers of Medical Breakthroughs.

Travassos R, Martins S, Fernandes A, Correia J, Melo R Int J Mol Sci. 2024; 25(12).

PMID: 38928403 PMC: 11204272. DOI: 10.3390/ijms25126699.

References

Zhu W, El-Nachef D, Yang X, Ledee D, Olson A . O-GlcNAc Transferase Promotes Compensated Cardiac Function and Protein Kinase A O-GlcNAcylation During Early and Established Pathological Hypertrophy From Pressure Overload. J Am Heart Assoc. 2019; 8(11):e011260. PMC: 6585351. DOI: 10.1161/JAHA.118.011260. View

Lock J, Sinkins W, Schilling W . Effect of protein S-glutathionylation on Ca2+ homeostasis in cultured aortic endothelial cells. Am J Physiol Heart Circ Physiol. 2010; 300(2):H493-506. PMC: 3044059. DOI: 10.1152/ajpheart.01073.2010. View

Hoffman J . Congenital heart disease: incidence and inheritance. Pediatr Clin North Am. 1990; 37(1):25-43. DOI: 10.1016/s0031-3955(16)36830-4. View

Chen H, Sun W, Zhu J, Yuan H, Chu M, Wen B . Modification of cardiac transcription factor Gata6 by SUMO. Biochimie. 2020; 170:212-218. DOI: 10.1016/j.biochi.2020.01.014. View

Hirschey M, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard D . SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature. 2010; 464(7285):121-5. PMC: 2841477. DOI: 10.1038/nature08778. View

Choi S, Chung S, Park K . Re-highlighting the action of PPARγ in treating metabolic diseases. F1000Res. 2018; 7. PMC: 6058466. DOI: 10.12688/f1000research.14136.1. View

Nonaka K, Kume N, Urata Y, Seto S, Kohno T, Honda S . Serum levels of S-glutathionylated proteins as a risk-marker for arteriosclerosis obliterans. Circ J. 2006; 71(1):100-5. DOI: 10.1253/circj.71.100. View

Roth G, Johnson C, Abajobir A, Abd-Allah F, Abera S, Abyu G . Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017; 70(1):1-25. PMC: 5491406. DOI: 10.1016/j.jacc.2017.04.052. View

Gogna R, Madan E, Khan M, Pati U, Kuppusamy P . p53's choice of myocardial death or survival: Oxygen protects infarct myocardium by recruiting p53 on NOS3 promoter through regulation of p53-Lys(118) acetylation. EMBO Mol Med. 2013; 5(11):1662-83. PMC: 3840484. DOI: 10.1002/emmm.201202055. View

10.

Ezzitouny M, Rosello-Lleti E, Portoles M, Sanchez-Lazaro I, Arnau-Vives M, Tarazon E . Value of SERCA2a as a Biomarker for the Identification of Patients with Heart Failure Requiring Circulatory Support. J Pers Med. 2021; 11(11). PMC: 8622248. DOI: 10.3390/jpm11111122. View

11.

Park S, Ozden O, Jiang H, Cha Y, Pennington J, Aykin-Burns N . Sirt3, mitochondrial ROS, ageing, and carcinogenesis. Int J Mol Sci. 2011; 12(9):6226-39. PMC: 3189778. DOI: 10.3390/ijms12096226. View

12.

Tanai E, Frantz S . Pathophysiology of Heart Failure. Compr Physiol. 2016; 6(1):187-214. DOI: 10.1002/cphy.c140055. View

13.

Budde K, Sommerer C, Rissling O, Dieterlen M, Barten M . Target Enzyme Activity and Phosphorylation of Pathway Molecules As Specific Biomarkers in Transplantation. Ther Drug Monit. 2016; 38 Suppl 1:S43-9. DOI: 10.1097/FTD.0000000000000288. View

14.

An L, Liu Q, Feng H, Bai X, Dang Y, Li C . Increased glycoprotein acetylation is associated with high cardiac event rates: Analysis using coronary computed tomography angiography. Anatol J Cardiol. 2018; 20(3):152-158. PMC: 6237945. DOI: 10.14744/AnatolJCardiol.2018.01058. View

15.

Hershberger K, Abraham D, Liu J, Locasale J, Grimsrud P, Hirschey M . Ablation of in the postnatal mouse heart results in protein succinylation and normal survival in response to chronic pressure overload. J Biol Chem. 2018; 293(27):10630-10645. PMC: 6036188. DOI: 10.1074/jbc.RA118.002187. View

16.

Chen M, Yi B, Sun J . Inhibition of cardiomyocyte hypertrophy by protein arginine methyltransferase 5. J Biol Chem. 2014; 289(35):24325-35. PMC: 4148861. DOI: 10.1074/jbc.M114.577494. View

17.

Mailloux R, Xuan J, McBride S, Maharsy W, Thorn S, Holterman C . Glutaredoxin-2 is required to control oxidative phosphorylation in cardiac muscle by mediating deglutathionylation reactions. J Biol Chem. 2014; 289(21):14812-28. PMC: 4031535. DOI: 10.1074/jbc.M114.550574. View

18.

Wang L, Wang P, Xu S, Li Z, Duan D, Ye J . The cross-talk between PARylation and SUMOylation in C/EBPβ at K134 site participates in pathological cardiac hypertrophy. Int J Biol Sci. 2022; 18(2):783-799. PMC: 8741850. DOI: 10.7150/ijbs.65211. View

19.

Wang T, Cao Y, Zheng Q, Tu J, Zhou W, He J . SENP1-Sirt3 Signaling Controls Mitochondrial Protein Acetylation and Metabolism. Mol Cell. 2019; 75(4):823-834.e5. DOI: 10.1016/j.molcel.2019.06.008. View

20.

Cai Z, Wang Z, Yuan R, Cui M, Lao Y, Wang Y . Redox-sensitive enzyme SENP3 mediates vascular remodeling via de-SUMOylation of β-catenin and regulation of its stability. EBioMedicine. 2021; 67:103386. PMC: 8138600. DOI: 10.1016/j.ebiom.2021.103386. View